NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. (NYSE:KDMN) (“Kadmon” or the “Company”) today provided an update on upcoming milestones and recent achievements, and reported financial and operational results for the fourth quarter and full year ended December 31, 2016.
“Kadmon continues to advance our robust clinical pipeline programs, setting the stage for multiple near-term inflection points,” said Harlan W. Waksal, M.D., President and Chief Executive Officer at Kadmon. “In 2017, we expect to report data from our three ongoing Phase 2 clinical studies of KD025, our selective ROCK2 inhibitor, in autoimmune and fibrotic diseases, as well as initiate three new clinical trials of tesevatinib in oncology and in polycystic kidney disease (PKD). We look forward to executing on these upcoming milestones.”
“Kadmon continues to advance our robust clinical pipeline programs, setting the stage for multiple near-term inflection points,” said Harlan W. Waksal, M.D., President and Chief Executive Officer at Kadmon. “In 2017, we expect to report data from our three ongoing Phase 2 clinical studies of KD025, our selective ROCK2 inhibitor, in autoimmune and fibrotic diseases, as well as initiate three new clinical trials of tesevatinib in oncology and in polycystic kidney disease (PKD). We look forward to executing on these upcoming milestones.”
